Kidney transplantation from non heart beating donors for end-stage renal disease
Conditions
Interventions
Trade Name: Sirolimus (Rapamune)
Product Name: Sirolimus
Pharmaceutical Form: Tablet
Sponsors
Newcastle upon Tyne Hospitals NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Recipients of kidneys from non heart beating donors Age 18-75 Written informed consent obtained from the patient after receiving a comprehensive explanation Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Pregnant women Recipients of multiple transplants (e.g. Both kidneys from one donor transplanted into one recipient or a simultaneous kidney and liver or kidney and pancreas transplant)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To compare the effects of sirolimus and tacrolimus on kidney function following non heart beating donor kidney transplantation into adult recipients.;Secondary Objective: To determine if the drugs have different effects on patient survival, survival of the transplanted kidney, acute rejection, chronic rejection and complications following surgery.;Primary end point(s): The primary end points are creatinine and calculated GFR (glomerular filtration rate) at monthly intervals from the date of transplant to 12 months. | — |
Countries
United Kingdom
Outcome results
None listed